Physician profile
Evan Jay
NPI 1366812836
$17,165.70
in general payments reported to CMS, 2019-2025
28 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.40 · 2022: $241 · 2023: $2,249 · 2024: $1,383 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,213 · Food and Beverage: $3,980 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,375 · Travel and Lodging: $3,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,212.50 |
| Food and Beverage | $3,980.03 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,375.00 |
| Travel and Lodging | $3,320.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $8,533.22 | 2023-2025 | Nalu Neurostimulation System |
| Globus Medical, INC. | $4,358.43 | 2025 | Vyrsa V1, Senza |
| Relievant Medsystems, INC. | $1,524.83 | 2023 | Intracept |
| Boston Scientific Corporation | $783.80 | 2024-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Collegium Pharmaceutical, INC. | $255.77 | 2022-2025 | Belbuca, Xtampza |
| Nevro Corp. | $212.65 | 2023-2024 | Senza |
| Protega Pharmaceutials INC | $197.93 | 2023-2024 | Roxybond |
| Medtronic, INC. | $188.39 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Janssen Pharmaceuticals, INC | $186.90 | 2021-2024 | Spravato |
| Averitas Pharma INC. | $177.34 | 2023-2025 | Qutenza |
| Spr Therapeutics, INC | $95.73 | 2024 | Sprint Pns System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.54 | 2024-2025 | Relistor |
| Foundation Fusion Solutions, LLC | $69.67 | 2024-2025 | |
| Valinor Pharma, LLC | $67.15 | 2024-2025 | Movantik |
| Vertos Medical, INC. | $64.42 | 2024 | Mild Device Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $43.07 | 2023-2025 | Evoke, Evoke Scs |
| Abbott Laboratories | $40.66 | 2025 | Eterna, Proclaim |
| Mml US, INC. | $34.89 | 2025 | Reactiv8 |
| Forte Bio-Pharma LLC | $33.99 | 2025 | Prolate, Tanlor, Nalocet |
| Alkermes, INC. | $33.99 | 2024-2025 | Aristada, Lybalvi |
| Sanofi-Aventis U.S. LLC | $30.18 | 2022-2023 | |
| Redhill Biopharma INC. | $30.00 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $28.63 | 2023 | Seglentis |
| Bioventus LLC | $22.62 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.18 | 2025 | Caplyta |
| Abbvie INC. | $18.09 | 2025 | |
| Tonix Medicines, INC. | $17.70 | 2025 | Tonmya |
| Vertex Pharmaceuticals Incorporated | $15.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Jay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.